Advocacy intelligence hub — real-time data for patient organizations
Epclusa: FDA approved
treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin
MAVYRET: FDA approved
MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
Sovaldi: FDA approved
Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs3
Epclusa
(sofosbuvir and velpatasvir)Orphan drugGilead Sciences, Inc.
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
12.1 Mechanism of Action EPCLUSA is a fixed-dose combination of sofosbuvir and velpatasvir, which are direct-acting antiviral agents against the hepat...
MAVYRET
(glecaprevir and pibrentasvir)Orphan drugAbbVie, Inc.
Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]
12.1 Mechanism of Action Mechanism of Action MAVYRET is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral ag...
Sovaldi
(sofosbuvir)Orphan drugGilead Sciences, Inc.
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
12.1 Mechanism of Action Sofosbuvir is a direct-acting antiviral agent against the hepatitis C virus [see Microbiology (12.4) ].
Andrew McGovern, MD
Momentum Data
Guy D Eslick
The Australian Paediatric Surveillance Unit;The University of Sydney
Elizabeth J Elliott
The University of Sydney
Robert Booy
The University of Sydney
Gulam Khandaker
Central Queensland Hospital and Health Service
Anne Morris
The Australian Paediatric Surveillance Unit;The University of Sydney